Popular Trials
Glycopeptide Antibiotic
Vancomycin vs Probiotics for Clostridium Difficile Infection
This trial is testing probiotics and an antibiotic called vancomycin in hospitalized patients who have C. difficile bacteria in their gut and are starting antibiotics. The goal is to find the best way to prevent these patients from getting a C. difficile infection. Probiotics have been studied and shown promising effects in preventing Clostridium difficile-associated diarrhea (CDAD).
Behavioural Intervention
Universal Gloving for C. Difficile Infection
This trial will compare the effectiveness of universal gloving practices to the standard of care in order to determine if the former can help prevent healthcare-associated Clostridium difficile infections.
Antibiotic
Standard of Care +1 More for C. Difficile
This trial is testing a new drug, DNV3837, to see if it is safe and effective in treating people with Clostridium difficile infection (CDI). The study will be conducted in two parts, with a total of 40 subjects enrolled. Part 1 will enroll 10 subjects and Part 2 will enroll up to 30 subjects. Treatment will consist of a daily IV infusion for 10 days. The objectives of the study are to evaluate the safety and efficacy of DNV3837, assess the drug's pharmacokinetics, and assess changes in the gut microbiome.
Microbiome Therapy
Fecal Microbiota Transplant for Clostridium Difficile and IBD
This trial will study the safety and effectiveness of Fecal Microbiota Transplants (FMT) in children with recurrent C. Difficile infections, with or without Inflammatory Bowel Disease (IBD). 454 pyrosequencing will be used to study the gut microbiota before and after transplantation.
Popular Filters
Trials for C. Diff Patients
Microbiome Therapy
Stool for Clostridium Difficile
This study was developed in response to the July, 2013 FDA draft guidance regarding FMT for CDI. The weight of the evidence in the literature suggests that FMT is the most effective treatment for ambulatory outpatients affected by recurrent CDI who fail conventional therapy. The anticipated benefits to research patients enrolled in this study include resolution of chronic diarrhea, return of bowel habits and nutritional status to normal, and resolution of chronic recurrent CDI. FMT involves the endoscopic instillation of freshly obtained stool with millions of live bacteria into the recipient's colon by endoscopic lavage. With any endoscopic procedure, there is a risk of perforated viscous. This is very rare, but the risk is increased with severe CDI. The risk of acquisition of communicable enteric or blood borne pathogen appears to be negligible.
Probiotic
Theralac probiotic +1 More for Clostridium Difficile Diarrhea
We have designed this study to measure the effect of normal flora supplementation, using available probiotics, on the incidence of Clostridium difficile-associated diarrhea in a population of general inpatients who are receiving antibiotics.
Microbiota Transplantation
Fecal Microbiota Transplantation for Clostridioides difficile Colitis
This trial is to confirm and extend the work of Trede and Rask-Madsen that administration of a defined fecal microbiota will lead to rapid and sustained resolution of C. difficile associated chronic relapsing diarrhea.
Trials for Clostridium Difficile Infection Patients
Microbiota Restoration
Lyophilized Fecal Microbiota Transplantation for Clostridium Difficile Infection
The primary goal is to study participants with recurrent C. difficile infection (CDI) treated with lyophilized fecal microbiota transplantation (FMT). The safety, clinical response and relapse rate in patients will be assessed.
Antibiotic
Extended Vancomycin Treatment for Clostridium Difficile Infection
This trial tests if extending vancomycin treatment with a gradually reduced dose can prevent recurrence of Clostridium difficile infection in adults. The idea is that a longer, gradually reduced antibiotic course will better eliminate the bacteria and lower the risk of the infection coming back. Vancomycin taper regimens are commonly used for the treatment of recurrent Clostridium difficile infections.
Polyclonal Antibodies
IM-01 for Clostridium Difficile Infection
This trial tests a new treatment using antibodies from chicken eggs for patients with mild to moderate C. difficile infections. These patients often don't respond well to antibiotics, and the new treatment aims to neutralize the harmful parts of the bacteria causing the infection. Egg yolk-derived antibodies have been explored as a novel approach for preventing infections.
Trials With No Placebo
Microbiota Restoration
Lyophilized Fecal Microbiota Transplantation for Clostridium Difficile Infection
The primary goal is to study participants with recurrent C. difficile infection (CDI) treated with lyophilized fecal microbiota transplantation (FMT). The safety, clinical response and relapse rate in patients will be assessed.
Microbiome Therapy
Stool for Clostridium Difficile
This study was developed in response to the July, 2013 FDA draft guidance regarding FMT for CDI. The weight of the evidence in the literature suggests that FMT is the most effective treatment for ambulatory outpatients affected by recurrent CDI who fail conventional therapy. The anticipated benefits to research patients enrolled in this study include resolution of chronic diarrhea, return of bowel habits and nutritional status to normal, and resolution of chronic recurrent CDI. FMT involves the endoscopic instillation of freshly obtained stool with millions of live bacteria into the recipient's colon by endoscopic lavage. With any endoscopic procedure, there is a risk of perforated viscous. This is very rare, but the risk is increased with severe CDI. The risk of acquisition of communicable enteric or blood borne pathogen appears to be negligible.
Frequently Asked Questions
Introduction to clostridium difficile
What are the top hospitals conducting clostridium difficile research?
Clostridium difficile, commonly known as C. difficile, is a formidable bacterium that causes severe gastrointestinal infections. While its prevalence can be concerning, there are hospitals at the forefront of tackling this infectious disease through clinical trials. In Hines, Illinois, the Edward Hines Jr. VA Hospital is actively engaged in two ongoing trials dedicated to understanding and combating C. difficile infections. Similarly, the VA Portland Health Care System in Oregon and Clement J. Zablocki VA Medical Center in Milwaukee have also prioritized this battle with two active clostridium difficile trials each.
In Philadelphia's Children's Hospital and the University of Pittsburgh Medical Center (UPMC), world-renowned institutions are joining forces to unravel the mysteries surrounding this challenging infection through their respective two and one active clostridium difficile trials.
It may come as a surprise that despite being such critical healthcare providers, none of these top hospitals has previously conducted any specific clinical trial solely focused on combatting C.difficile before now; however their current dedication shows promising progress towards gaining further insights into effective prevention and treatment options for patients affected by it.
While Clostridium difficile can cause debilitating symptoms and pose risks to vulnerable populations such as children or veterans who rely on specialized medical care offered by these distinguished facilities - but thanks to these hospitals' relentless pursuit of innovative solutions even for niche conditions like C.difficle; we might soon witness significant breakthroughs which will ultimately benefit not only those directly impacted but also contribute towards global health improvements initiatives
Which are the best cities for clostridium difficile clinical trials?
Calgary, Alberta; Milwaukee, Wisconsin; Durham, North carolina; Philadelphia, Pennsylvania; and Baltimore, Maryland are the top cities for clostridium difficile (CDI) clinical trials. Each city has 3 active trials focusing on different aspects of CDI treatment and prevention. From testing the efficacy of RBX2660 to studying the impact of universal gloving and investigating alternative treatments like Fidaxomicin, these clinical trials aim to advance our understanding of CDI management and develop better strategies for combating this challenging infection.
Which are the top treatments for clostridium difficile being explored in clinical trials?
Clinical trials are shedding light on the top treatments for Clostridium difficile, a challenging infection to tackle. Among the leading contenders in these trials are:
- Fecal microbiota transplantation (FMT)
- Bezlotoxumab
FMT is gaining traction as a potential game-changer, with its ability to restore healthy gut bacteria and combat C. difficile infections. Meanwhile, bezlotoxumab is showing promise as a monoclonal antibody that can prevent recurrent infections by targeting toxins produced by C. difficile. These innovative approaches hold significant hope for patients battling this persistent infection.
What are the most recent clinical trials for clostridium difficile?
Exciting developments in the field of clostridium difficile research offer hope for improved management and treatment strategies. One recent clinical trial investigated the efficacy of chlorhexidine, a powerful antiseptic agent, in combating clostridium difficile infections. Another study explored an extended vancomycin regimen as an intervention method against this challenging infection. These trials provide valuable insights into potential approaches for addressing clostridium difficile, offering promising avenues to enhance patient outcomes and reduce the burden of this disease.
What clostridium difficile clinical trials were recently completed?
Recently completed clinical trials for Clostridium difficile, a bacterium that can cause severe gastrointestinal infections, have yielded valuable insights. One such study involved the investigation of Uproleselan as a potential treatment option for this challenging infection. Additionally, researchers evaluated the efficacy and safety of mRNA-1273 in combating Clostridium difficile infections. These groundbreaking advancements underline the dedication of researchers in their pursuit to combat this persistent bacterium and offer hope for those affected by its debilitating effects.